FDA Hepatitis Update - Important updates to PegIntron labeling
On December 22, 2011, the Food and Drug Administration approved revisions to the product labeling for
PegIntron to include the use of
PegIntron with hepatitis C virus (HCV) NS3/4A protease inhibitors for the treatment of genotype 1, chronic hepatitis C (CHC) infection. Additionally, the product labeling was update to include revisions to the text regarding the use of PegIntron in patients with neuropsychiatric disorders.